All 2024 International AIDS Conference articles
-
NewsExploratory analysis associates HIV drug abacavir with elevated cardiovascular disease risk in large global trial
Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, according to an exploratory analysis from a large international clinical trial primarily funded by the National Institutes of Health (NIH). There ...
-
NewsLong-acting injectable cabotegravir for HIV prevention is safe in pregnancy
Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study.
-
NewsIsolated viral load test may generate false positive results for people using long-acting PrEP
A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.
